Clinical pharmacology and clinical trials in Japan

被引:0
|
作者
Ebihara, A
Takahashi, K
Ikemoto, F
Yamamoto, K
机构
[1] BANYU PHARMACEUT CO LTD, DEPT CLIN RES, MEGURO KU, TOKYO 153, JAPAN
[2] BANYU PHARMACEUT CO LTD, DEV RES LABS, MENUMA, JAPAN
[3] OSAKA CITY UNIV, OSAKA 558, JAPAN
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 1996年 / 74卷 / 08期
关键词
clinical pharmacology; clinical trials; drug development; drug therapeutics; informed consent;
D O I
暂无
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Clinical pharmacology is the pursuit of rational therapeutics by following the scientific principles of medicine and pharmacology. In Japan the roles for clinical pharmacology and clinical pharmacologists have been evolving since the discipline appeared in the 1950s. Clinical pharmacology and clinical trials for drug development depend on each other, and clinical pharmacologists play an important role in drug development in Japan. As the discipline becomes more important and complicated, many issues regarding drug therapeutics and clinical trials in Japan have been raised, and several points of view have been expressed. The following suggestions have been made to improve clinical pharmacology in Japan: (a) Medical education in the field of clinical pharmacology must be improved by creating or improving clinical pharmacology programs in medical schools. (b) The appropriate infrastructure for clinical trials must be established so that the physicians' workload is reduced, and patients' participation in clinical trials becomes much easier. (c) Scientific and ethical standards of the pharmaceutical industry must be improved, and the effort should be made to produce drugs with new mechanisms of action or with significant expected benefits. (d) The regulatory agency must provide stronger support, encompassing all the various points of view of academic institutes and the pharmaceutical industry. In light of the enthusiasm demonstrated by the government, physicians, and pharmaceutical industry in Japan for continued progress in clinical pharmacology, it seems likely that all its challenges will be overcome in the near future. Hence, despite the various problems discussed here the future seems promising for the continued development of clinical pharmacology.
引用
收藏
页码:479 / 486
页数:8
相关论文
共 50 条
  • [21] Clinical trials in Japan and the United States
    Alexander, JH
    AMERICAN HEART JOURNAL, 2004, 147 (02) : 200 - 201
  • [22] Prevention of misconduct in clinical trials in Japan
    Yui, Yoshiki
    LANCET, 2014, 384 (9948): : 1098 - 1098
  • [23] CLINICAL-TRIALS WITH INTERFERON IN JAPAN
    IMANISHI, J
    KISHIDA, T
    TEXAS REPORTS ON BIOLOGY AND MEDICINE, 1982, 41 : 647 - 652
  • [24] Clinical trials for malignant lymphoma in Japan
    Tobinai, K
    Hotta, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (07) : 369 - 378
  • [25] Critical changes in clinical trials in Japan
    Ichikawa, S
    Tamaki, M
    DRUG INFORMATION JOURNAL, 2001, 35 (02): : 493 - 495
  • [26] Critical Changes in Clinical Trials in Japan
    Shuichi Ichikawa
    Masatake Tamaki
    Drug information journal : DIJ / Drug Information Association, 2001, 35 (2): : 493 - 495
  • [27] Current Status of Clinical Trials and Good Clinical Practice in Japan
    Tominaga T.
    Drug information journal : DIJ / Drug Information Association, 1997, 31 (4): : 1071 - 1078
  • [28] Inclusion of women in clinical drug trials reported in Clinical Pharmacology & Therapeutics (CPT) and the British Journal of Clinical Pharmacology (BJCP) 2001
    Thürmann, PA
    Fleisch, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (07) : S85 - S85
  • [29] Efficient Clinical Trials in Japan: Bridging Studies Versus Participation in Global Clinical Trials
    Shirotani, Mari
    Suwa, Toshio
    Kurokawa, Tatsuo
    Chiba, Koji
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (04): : 438 - 445
  • [30] Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
    Mannargudi, Mukundan Baskar
    Deb, Subrata
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (08) : 1499 - 1529